In any event, our data are consistent with the oncogenic role proposed for CSN53 and the CSN3 protein54 in different tumor types, and highlight the possibility that the CSN/PKD complex might be a potential molecular target for design of new therapeutic drugs. The gene discussed is CSN3; the disease is neoplasm.